SP-102 Granted Fast Track Designation From The FDA
Semnur Pharmaceuticals Announces The Launch Of The New Clinical Trial Website at www.clearbackpainstudy.com.
Mountain View, Calif., Jan 7, 2018 /PRNewswire/ – Semnur Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company focused on developing and commercializing novel therapeutics for pain, announced the start of a pivotal Phase 3 clinical trial in the U.S. to evaluate its lead product SP-102 in patients with lumbar radicular pain/sciatica. In addition, the U.S. Food and Drug Administration (FDA) has granted SP-102 Fast Track Designation for the treatment of lumbar radicular pain/sciatica.
